MALAYSIA PARTNERS WITH JAPAN'S TOP ONCOLOGY HOSPITAL TO FOCUS ON ONCOLOGY DRUG DEVELOPMENT

KUALA LUMPUR, Nov 2 (Bernama) -- Clinical Research Malaysia inked a Memorandum of Understanding (MoU) with the National Cancer Center Hospital to develop Malaysia’s capabilities and capacities in oncology clinical research. As one of the partners in Asia for the ATLAS (Asian clinical TriaLs network for cAncerS) project established by the National Cancer Center Japan (NCCJ), Malaysia will benefit from early phase oncology drug development, cancer genomic medicine advancement and drug access and development. The National Cancer Center Hospital (NCCH) that will be leading this project, is the region’s leading cancer hospital located in Tokyo and was recently rated Top 20 among ‘World’s Best Specialized Hospitals 2021 in Oncology’ by Newsweek. It was designated an AMED (Japan Agency for Medical Research and Development) Global Clinical Trial Core Center in 2016 and has since scaled up its international clinical trials activities.  Clinical Research Malaysia (CRM) as a site management organization under the Malaysia Ministry of Health has vast experience in managing more than 1400 international multicentre clinical trials including oncology since 2012. Malaysia has a healthy number of clinical research sites, experienced investigators with a matured clinical research ecosystem and competitive start-up timeline in the region. The MoU with NCCH spells out collaboration in the areas of cancer research that includes infrastructure development, training opportunities in clinical research, participation in rare cancer clinical trial, networking opportunities as well as visits/attachments by research experts from both countries. This will further pave the way for better Malaysia-Japan collaborations in advancing drug development. “Upon launching the ATLAS project for establishing a clinical research network with our Asian partners, CRM stood out as the experienced and reliable partner to the project, as well as being the most forthcoming in collaborating with us. Through implementing this ambitious project, we wish to establish a sustainable clinical trial network, share capacity building opportunities, and facilitate early drug development. Through clinical trials in Asia, we can bring about better cancer treatments, eventually delivering to cancer patients in Asia,” said Dr. Kazuaki Shimada, Director of the NCCH. http://mrem.bernama.com/viewsm.php?idm=38571